A compound having a structure of formula (I): ##STR00001##
Wherein each of R.sub.1A, R.sub.1B, R.sub.1C, R.sub.1D, R.sub.1E and R.sub.1F is independently selected from the group consisting of a hydrogen atom, a hydroxide group, and a substituted or unsubstituted C.sub.1-C.sub.8 alkoxy group, R.sub.2 is selected from the group consisting of a hydrogen atom and a hydroxide group, R.sub.3 is hydrogen atom, R.sub.4 is selected from the group consisting of a hydrogen atom, a C.sub.1-C.sub.3 alkyl group, and a C.sub.1-C.sub.3 fluoroalkyl group, R.sub.5 is selected from the group consisting of a hydrogen atom, a C.sub.1-C.sub.6 alkyl, and a C.sub.1-C.sub.6 fluoroalkyl, n is 1 or 2, and X is a negatively charged anion. Removal of the substituted nitroimidazole affords a phenanthroindolizidine or phenanthroquinolizidine alkaloid derivative. The compound is used in a pharmaceutical composition and a method of treating a proliferative disease.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

##STR00001##

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

##STR00001##

Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. Certain compounds and salts of Formula I are active as Top1 and/or Tdp1 inhibitors. The disclosure provides pharmaceutical compositions containing a compound of Formula I as the only active agent, or optionally containing one or more additional active agents. Methods of using compounds of Formula I to treat cancer are provided in this disclosure. The disclosed compounds of Formula I may be used alone to treat cancer, but may also be used in combination with another active agent, such as a Top1 inhibitor, for example, camptothecin or a camptothecin analogue.

Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. Certain compounds and salts of Formula I are active as Top1 and/or Tdp1 inhibitors. The disclosure provides pharmaceutical compositions containing a compound of Formula I as the only active agent, or optionally containing one or more additional active agents. Methods of using compounds of Formula I to treat cancer are provided in this disclosure. The disclosed compounds of Formula I may be used alone to treat cancer, but may also be used in combination with another active agent, such as a Top1 inhibitor, for example, camptothecin or a camptothecin analogue.

The present invention relates to compounds that include a nitrogen heteroatom, including a compound of the formula (I). Also provided herein is an organic electronic device comprising the compound and a display device or lighting device comprising the organic electronic device.

The present invention relates to compounds that include a nitrogen heteroatom, including a compound of the formula (I). Also provided herein is an organic electronic device comprising the compound and a display device or lighting device comprising the organic electronic device.

The present invention relates to an organic electroluminescent device, particularly to an organic light emitting diode (OLED) including an ETL stack of at least two electron transport layers, wherein the first electron transport layer comprises a first electron transport matrix compound and the second electron transport layer comprises second electron transport matrix compound and a redox n-dopant, and a device comprising the OLED.

The present invention relates to an organic electroluminescent device, particularly to an organic light emitting diode (OLED) including an ETL stack of at least two electron transport layers, wherein the first electron transport layer comprises a first electron transport matrix compound and the second electron transport layer comprises second electron transport matrix compound and a redox n-dopant, and a device comprising the OLED.

The present invention relates to compounds of the formula (I), a process for its preparation and its use as fluorescent dye that absorbs light emitted from an irradiation source and emits light different from that of the irradiation source and having a wavelength in the range from 680 to 950 nm; in photovoltaic applications; or as semiconductor in organic electronic applications; as laser dye, in an ink for machine readability and/or security applications or for the laser-welding of plastics; or for brand protection or as marker for liquids. The compounds of formula (I) may have a high fluorescence quantum yield, a high molar extinction coefficient, a high solubility and stability in the application medium, good storage stability and/or good detectability even in very small amounts in the correspondingly marked liquids.

##STR00001##